Across TCGA pan-cancer cohorts, LINC01350 RNA is linked to patient survival in 14 of 34 cancer types, making it the most broadly survival-associated LINC01350 data layer.
The strongest signal is observed in cholangiocarcinoma (CHOL), where higher LINC01350 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated LINC01350 expression acts as an unfavorable survival marker, although some lineages such as LGG show a favorable association.
CHOL, KIRP, and ACC are the cancer types where LINC01350 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.